43 related articles for article (PubMed ID: 1850382)
21. Immune regulation in Epstein-Barr virus-associated diseases.
Khanna R; Burrows SR; Moss DJ
Microbiol Rev; 1995 Sep; 59(3):387-405. PubMed ID: 7565411
[TBL] [Abstract][Full Text] [Related]
22. Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.
Pither RJ; Zhang CX; Shiels C; Tarlton J; Finerty S; Morgan AJ
J Virol; 1992 Feb; 66(2):1246-51. PubMed ID: 1370550
[TBL] [Abstract][Full Text] [Related]
23. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
24. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients].
Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW
Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins.
Littler E; Baylis SA; Zeng Y; Conway MJ; Mackett M; Arrand JR
Lancet; 1991 Mar; 337(8743):685-9. PubMed ID: 1672175
[TBL] [Abstract][Full Text] [Related]
26. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus vaccines.
Morgan AJ
Vaccine; 1992; 10(9):563-71. PubMed ID: 1323899
[TBL] [Abstract][Full Text] [Related]
28. ELISA tests and monoclonal antibodies for EBV.
Pearson GR
J Virol Methods; 1988 Sep; 21(1-4):97-104. PubMed ID: 2846624
[TBL] [Abstract][Full Text] [Related]
29. Control of viral disease: the development of Epstein-Barr virus vaccines.
Morgan AJ
Springer Semin Immunopathol; 1991; 13(2):249-62. PubMed ID: 1664989
[No Abstract] [Full Text] [Related]
30. Antiviral activities in human saliva.
Malamud D; Abrams WR; Barber CA; Weissman D; Rehtanz M; Golub E
Adv Dent Res; 2011 Apr; 23(1):34-7. PubMed ID: 21441478
[TBL] [Abstract][Full Text] [Related]
31. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
Yao QY; Rowe M; Morgan AJ; Sam CK; Prasad U; Dang H; Zeng Y; Rickinson AB
Int J Cancer; 1991 Apr; 48(1):45-50. PubMed ID: 1850382
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
